Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
146 results about "Cell surface molecules" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Cell-surface receptors, also known as transmembrane receptors, are cell surface, membrane-anchored, or integral proteins that bind to external ligand molecules. This type of receptor spans the plasma membrane and performs signal transduction, converting an extracellular signal into an intracellular signal.
Degraded agonist antibody
InactiveUS20040242847A1Excellent antigen-binding propertyExcellent agonist activityPeptide/protein ingredientsAntibody mimetics/scaffoldsDiseaseAntiendomysial antibodies
The invention relates to a modified antibody which contains two or more H chain V regions and two or more L chain V regions of monoclonal antibody and can transduce a signal into cells by crosslinking a cell surface molecule(s) to thereby serve as an agonist. The modified antibody can be used as a signal transduction agonist and, therefore, useful as a preventive and / or remedy for various diseases such as cancer, inflammation, hormone disorders and blood diseases.
Owner:CHUGAI PHARMA CO LTD
Degraded agonist antibody
InactiveUS20090311718A1Eliminate side effectsMethod is newPeptide/protein ingredientsAntipyreticMonoclonal antibodyV region
The invention relates to a modified antibody which contains two or more H chain V regions and two or more L chain V regions of monoclonal antibody and can transduce a signal into cells by crosslinking a cell surface molecule(s) to thereby serve as an agonist. The modified antibody can be used as a signal transduction agonist and, therefore, useful as a preventive and / or remedy for various diseases such as cancer, inflammation, hormone disorders and blood diseases.
Owner:CHUGAI PHARMA CO LTD
Antibody complexes
InactiveUS20070036783A1Reduce needImmunoglobulins against cell receptors/antigens/surface-determinantsMammal material medical ingredientsCell adhesionAdhesion process
This invention is directed to a soluble complex of ligands that binds to surface molecules of hemopoietic cells and result in their activation or expansion. The complex may be used in the activation and / or expansion of hemopoietic cells, optionally in combination with their transduction. The complex of ligands bind at least two cell surface molecules, such as one that plays a role in cell-cell adhesion and one that may or may not activate or stimulate the cell to promote growth and / or proliferation after binding to a ligand. A complex of ligands that bind two hemopoietic cell stimulatory molecules is also provided. The invention further provides for the use of the complex to target vectors to hemopoietic cells.
Owner:VIRXSYS
Nucleic acids encoding JTT-1 protein
InactiveUS7045615B2Increased proliferationImprove purification effectBacteriaPeptide/protein ingredientsCell adhesionAutoimmune responses
Novel cell surface molecules recognized by monoclonal antibodies against a cell surface molecule of lymphocytic cells that play an important role in autoimmune diseases and allergic diseases have been isolated, identified, and analyzed for their functions. The cell surface molecules are expressed specifically in thymocytes, lymphocytes activated by ConA-stimulation, and peripheral blood lymphocytes, and induce cell adhesion. Antibodies against the cell surface molecules significantly ameliorate pathological conditions of autoimmune diseases and allergic diseases.
Owner:JAPAN TOBACCO INC
Detecting receptor oligomerization
ActiveUS7105308B2Low backgroundHigh sensitivityMicrobiological testing/measurementBiological material analysisReceptorChemical compound
Methods are provided for detecting formation of oligomeric complexes of molecules on the surface of cell membranes. These methods employ pairs of tagged probes and cleaving probes, each of which binds specificly to a cell surface molecule. The tagged probe includes a molecular tag that is linked to a first binding compound through a cleavable linkage, and the cleaving probe includes a second binding agent and a cleavage-inducing moiety that can cleave the linkage when within a defined proximity thereto. Binding of the two probes to cell surface molecules that have formed an oligomeric complex results in release of the molecular tag from the binding compound, providing a measure of formation of the complex.
Owner:VIROLOGIC INCORPORATED
Agonist antibodies
InactiveUS20040058393A1Induce apoptosisExcellent antigen-binding propertyPeptide/protein ingredientsAntibody mimetics/scaffoldsDiseaseAntiendomysial antibodies
Modified antibodies containing 2 or more H chain V domains and or more L chain V domains of a monoclonal antibody which can transduce a signal into cells by crosslinking a cell surface molecule, thereby serving as an agonist. Because of being usable as agonists for signal transduction, these modified antibodies are useful as, for example, preventives and / or remedies for various diseases such as cancer, inflammation, hormone disorders and blood diseases.
Owner:CHUGAI PHARMA CO LTD
Yeast Display Systems
InactiveUS20110275535A1Peptide librariesConnective tissue peptidesYeast displayCell surface molecules
Owner:NOVARTIS AG
Treatment for CD5+ B cell lymphoma
InactiveUS20050054665A1Ameliorate at least one symptomDecrease in peripheral blood lymphocytes, lymphadenopathy, or splenomegalyBiocidePeptide/protein ingredientsTLR8Agonist
The present invention provides methods for increasing expression of cell surface molecules of CD5+ B cell lymphoma cells by contacting cells with immune response modifiers. The invention also provides methods for the treatment of CD5+ B cell lymphomas, including chronic lymphocytic leukemia and small lymphocytic lymphoma, by administering immune response modifier compounds to a subject in need of such treatment. Suitable immune response modifier compounds include agonists of TLR7 and / or TLR8.
Owner:COLEY PHARMA GRP INC
Potentiation of anti-CD38-Immunotoxin cytotoxicity
The present invention is directed to the use of agents that induce high levels of cell surface molecules to provide targets for immunotoxins directed against the same cell surface molecules. A specific example is given in which all-trans-retinoic acid (RA) is used to induce high levels of CD38 cell surface antigen expression in several myeloid and lymphoid leukemia cells. CD38 was then used as target for delivering plant toxin (gelonin) to leukemia cells. Treatment of leukemia cells with RA induced high levels of CD38 in those cells that otherwise had low CD38 expression. The RA-induced leukemia cells then became exquisitely sensitive to an immunotoxin constructed from an anti-CD38 monoclonal antibody conjugated to the plant toxin gelonin.
Owner:BOARD OF REGENTS
JTT-1 protein and methods of inhibiting lymphocyte activation
InactiveUS7112655B1Increased proliferationImprove purification effectCell receptors/surface-antigens/surface-determinantsPeptide/protein ingredientsBiological activationPeripheral blood lymphocyte
A cell surface molecule that is expressed specifically in thymocytes, lymphocytes activated by ConA-stimulation, and peripheral blood lymphocytes. This molecule is involved in signal transmission of the secondary signal (costimulatory signal) essential for the activation of lymphocytes such as T cells and regulates functions of activated lymphocytes such as activated T cells. Disclosed are a polypeptide of the cell surface molecule; a polypeptide fragment thereof; a fusion polypeptide comprising the fragment; a pharmaceutical composition comprising any one of the above; and methods of using the compositions.
Owner:JAPAN TOBACCO INC
Molecular and functional profiling using a cellular microarray
InactiveUS20060019235A1Faster and efficient predictionReward for identificationMicrobiological testing/measurementMaterial analysisCell–cell interactionFunctional profiling
Cells are profiled with respect to their expression of cell surface molecules, and ability to respond to external stimulus in the microenvironment. External stimuli include cell-cell interactions, response to factors, and the like. The cells are arrayed on a planar or three-dimensional substrate through binding to immobilized or partially diffused probes. Probes of interest include specific binding partners for cell surface molecules, signaling cues that act to regulate cell responses, differentiation factors, etc., which may be arrayed as one or a combination of molecules.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Antibodies to JTT-1 protein and cells secreting such antibodies
InactiveUS7196175B2Increased proliferationImprove purification effectBacteriaPeptide/protein ingredientsCell adhesionAdhesion process
Novel cell surface molecules recognized by monoclonal antibodies against a cell surface molecule of lymphocytic cells that play an important role in autoimmune diseases and allergic diseases have been isolated, identified, and analyzed for their functions. The cell surface molecules are expressed specifically in thymocytes, lymphocytes activated by ConA-stimulation, and peripheral blood lymphocytes, and induce cell adhesion. Antibodies against the cell surface molecules significantly ameliorate pathological conditions of autoimmune diseases and allergic diseases.
Owner:JAPAN TOBACCO INC
Product and process for T lymphocyte immunosuppression
InactiveUS6264950B1Peptide/protein ingredientsAntibody mimetics/scaffoldsMajor histocompatibilityActivation cells
The present invention relates to a product and process for suppressing an immune response using a T lymphocyte veto molecule capable of blocking cell surface molecules responsible for T cell activation. Disclosed is a CD4 or CD2 molecule, associated with an immunoglobulin molecule capable of binding to a major histocompatibility antigen. Also disclosed is a method to produce a T lymphocyte veto molecule, a therapeutic composition comprising a T lymphocyte veto molecule and methods to use T lymphocyte veto molecules in therapeutic processes requiring suppression of an immune response.
Owner:NAT JEWISH MEDICAL & RES CENT
Compounds and methods for diagnostic imaging and therapy
InactiveUS20050085417A1Special deliveryGenetic material ingredientsNucleic acid sequencingCell surface molecules
Compounds comprising a diagnostic or therapeutic moiety can be retained inside a cell by conjugating the moiety to at least one PNA that is targeted to the transcripts from a gene of interest. The diagnostic or therapeutic moiety is also conjugated to at least one targeting moiety specific for an extracellular receptor or other cell surface molecule. The targeting moiety binds to the surface of a cell, and the entire compound is then internalized. Once inside the cell, the PNA portion of the diagnostic or therapeutic compound binds to RNA transcripts in a sequence specific manner. Binding of the PNA to its target RNA transcript retains the compound within the cell. The PNA can be designed to bind to a predetermined nucleic acid sequence from an RNA transcript, for example a mutated or overexpressed sequence that is characteristic of a pathological state.
Owner:THAKUR MADHUKAR DR +1
Profiling frequencies of receptor heterodimers
InactiveUS7135300B2Low backgroundHigh sensitivityMicrobiological testing/measurementBiological material analysisDimerReceptor
Owner:MONOGRAM BIOSCIENCES
Measuring receptor homodimerization
InactiveUS7402398B2Low backgroundHigh sensitivityComponent separationMicrobiological testing/measurementEpitopeAnalyte
The invention provides methods and kits for detecting and / or measuring receptor homodimers on a cell surface membrane. In one aspect, the methods employ pairs of probes comprising binding compounds and a cleaving probe, such that at least one binding compound binds specifically to the same epitope of a membrane-bound analyte as the cleaving probe. The binding compound includes one or more molecular tags attached through a cleavable linkage, and the cleaving probe includes a cleavage-inducing moiety that can cleave the linkage when within a defined proximity thereto. Binding of the two probes to a homodimer of a cell surface molecules results in release of molecular tags from the binding compounds, providing a measure of formation of the homodimeric complex.
Owner:MONOGRAM BIOSCIENCES
Mutant polypeptide having effector function
InactiveUS20100080794A1Enhanced effector functionLess side effectsAntipyreticAnalgesicsHuman cellSugar
Mutant polypeptides of the present invention contain an Fc region in which a cysteine residue is substituted for the second amino acid from the glycosylation site to the N terminal side in the Fc region. The Fc region is preferably a human IgG Fc region. The mutant polypeptides of the present invention may also contain an N-linked sugar chain at the glycosylation site in Fc region. Furthermore, a polypeptide domain other than the Fc region of the mutant polypeptides of the present invention may be a polypeptide molecule that recognizes a human cell surface molecule.
Owner:MEDICAL & BIOLOGICAL LAB CO LTD +1
CC chemokine receptor 5 DNA, new animal models and therapeutic agents for HIV infection
InactiveUS7151087B2Effective in regulating monocyte accumulationEffective in regulating activationBiocidePeptide/protein ingredientsChemokine receptor D6Mammal
The susceptibility of human macrophages to human immunodeficiency virus (HIV) infection depends on cell surface expression of the human CD4 molecule and CC cytokine receptor 5. CCR5 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CCR5 plays an essential role in the membrane fusion step of infection by some HIV isolates. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and CCR5 provides valuable tools for the continuing research of HIV infection. In addition, antibodies which bind to CCR5, CCR5 variants, and CCR5-binding agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics for macrophage-tropic strains of HIV.
Owner:UNITED STATES OF AMERICA
Agonist antibodies
InactiveUS20040258684A1Easy to produceEfficiently dimerizedPeptide/protein ingredientsAntibody mimetics/scaffoldsDiseaseAntiendomysial antibodies
Modified antibodies containing 2 or more H chain V domains and or more L chain V domains of a monoclonal antibody which can transduce a signal into cells by crosslinking a cell surface molecule, thereby serving as an agonist. Because of being usable as agonists for signal transduction, these modified antibodies are useful as, for example, preventives and / or remedies for various diseases such as cancer, inflammation, hormone disorders and blood diseases.
Owner:CHUGAI PHARMA CO LTD
Modulation of novel immune checkpoint targets
PendingUS20190255107A1Decrease in exhausted T cell phenotypeIncrease T cell activationAntibacterial agentsCell receptors/surface-antigens/surface-determinantsDiseaseClinical efficacy
Dysfunctional or exhausted T cells arise in chronic diseases including chronic viral infections and cancer, and express high levels of co-inhibitory receptors. Therapeutic blockade of these receptors has clinical efficacy in the treatment of cancer. While co-inhibitory receptors are co-expressed, the triggers that induce them and the transcriptional regulators that drive their co-expression have not been identified. The immunoregulatory cytokine IL-27 induces a gene module in T cells that includes several known co-inhibitory receptors (Tim-3, Lag-3, and TIGIT). The present invention provides a novel immunoregulatory network as well as novel cell surface molecules that have an inhibitory function in the tumor microenvironment. The present invention further provides the novel discovery that the transcription factors Prdm1 and c-Maf cooperatively regulate the expression of the co-inhibitory receptor module. This critical molecular circuit underlies the co-expression of co-inhibitory receptors in dysfunctional T cells and identifies novel regulators of T cell dysfunction.
Owner:THE BRIGHAM & WOMEN S HOSPITAL INC +2
Cells expressing both human CD4 and a human fusion accessory factor associated with HIV infection
The susceptibility to human immunodeficiency virus (HIV) infection depends on the cell surface expression of the human CD4 molecule and a human fusion accessory factor associated with HIV infection (CXCR4). CXCR4 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CXCR4 plays an essential role in the membrane fusion step of HIV infection. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and CXCR4 provides valuable tools for the continuing research of HIV infection and the development of more effective anti-HIV therapeutics. In addition, antibodies against CXCR4, isolated and purified peptide fragments of CXCR4, and CXCR4-binding biologic agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics.
Owner:BERGER EDWARD +3
Methods and reagents for quantitation of cell-surface molecule expression on peripheral blood cells
InactiveUS6951727B2Stable expressionRapid and reliable quantitative measurement of HLA-DREnzymologyImmunoglobulins against cell receptors/antigens/surface-determinantsImmunologic CompetenceLysosome
Improved methods, reagents, and kits for quantitation of HLA-DR and / or CD11b expression on peripheral blood cells are presented. Inclusion of a lysosomotropic amine, such as chloroquine, during staining stabilizes HLA-DR and CD11b expression. Use of a novel anti-CD14 conjugate, anti-CD14-PerCP / CY5.5, permits the ready discrimination of monocytes. The improved methods, reagents, and kits may be used to assess immune competence, and to direct and monitor immunostimulatory therapies in septic patients exhibiting monocyte deactivation.
Owner:BECTON DICKINSON & CO
Design of Delivery Vehicle Based On Rolling Model
InactiveUS20090186073A1Improve developmentOrganic active ingredientsAntipyreticDelivery vehicleEngineering
Objects of the present invention are to provide a method for designing an optimum delivery preparation with the use of a convenient experiment and / or assay and to search for the thus produced delivery vehicle. The present invention provides a method for producing a delivery vehicle for achieving the delivery of a desired substance to a desired site, which comprises the steps of:A) measuring in vitro affinity of candidate delivery vehicles for a cell surface molecule such as a lectin associated with the site; andB) selecting a delivery vehicle having in vitro affinity corresponding to delivery to the desired site.
Owner:NAT INST OF ADVANCED IND SCI & TECH +1
Engineered immune cell and use thereof
ActiveCN111849910APromote differentiationPromote recruitmentVirusesAntibody mimetics/scaffoldsAutoimmune conditionWhite blood cell
The present invention relates to an engineered immune cell expressing (i) a cell surface molecule that specifically recognizes a ligand, (ii) an exogenous interleukin, and (iii) an exogenous Flt3L, XCL2, and / or XCL1. The invention also provides the use of the engineered immune cell in the treatment of cancer, infection or autoimmune disease. Compared with the traditional engineered immune cell, the engineered immune cell has remarkably improved tumor killing activity.
Owner:NANJING BIOHENG BIOTECH CO LTD
Receptor targeting constructs and uses thereof
ActiveUS20160331840A1Preventing cancer metastasisTreat cancerPowder deliveryOrganic active ingredientsMembrane penetrationBinding domain
Disclosed herein are drug delivery molecules that comprise a ligand that targets a cell surface molecule; a membrane penetration domain; and a payload binding domain; and pharmaceutical compositions comprising the same. Also disclosed are methods of treating cancer, inhibiting the progression of cancer, preventing cancer metastasis, and delivering a therapeutic compound to the brain in a subject in need thereof, the methods comprising identifying a subject in need thereof; providing a composition comprising the drug delivery molecule as disclosed herein; and administering an effective amount of the composition to the subject.
Owner:CEDARS SINAI MEDICAL CENT
Compositions and methods for producing dendritic cells
Described herein are compositions and methods for treating a disease, particularly a cancer, with primed dendritic cells recognizing a tumor antigen. The methods may comprise storing, shipping and / or culturing dendritic cells, where the dendritic cells are stored on a hard surface. Lysis protocols are described where the lysis does not result in complete lysis of cells in order to provide cell surface molecules maintained in a cell surface-embedded state. Non-lethal Dengue virus strains are also provided for therapeutic purposes.
Owner:PRIMEVAX IMMUNO ONCOLOGY INC
Liver x receptor agonists and uses thereof
InactiveUS20160324981A1Modulate its functionImmunoglobulins against cell receptors/antigens/surface-determinantsPharmaceutical non-active ingredientsTreatment effectAntibody fragments
Disclosed herein are antibody drug conjugates having an antibody or antibody fragment that binds a cell surface molecule on a target cell, wherein the target cell is a lymphocyte and a therapeutic agent that has a therapeutic effect in a subject in need thereof. Further disclosed herein are antibody drug conjugates having an antibody or antibody fragment that binds a cell surface molecule on a target cell; and a therapeutic agent that binds an intracellular moiety of the target cell. These antibody drug conjugates may be used for treating cardiovascular diseases.
Owner:THE SCRIPPS RES INST
Methods and compositions for discovery of target-specific antibodies using antibody repertoire array (ARA)
InactiveCN102164957AImmunoglobulins against cell receptors/antigens/surface-determinantsAntiviralsEpitopeTherapeutic antibody
The invention provides antibody arrays specific for target antigens. Methods for discovery and compositions comprising native human antibodies, arrays comprising such antibodies, immortalized B cells expressing such antibodies and non-immortalized B cell libraries comprising B cells expressing such antibodies are provided. The invention provides a method for screening monoclonal antibodies for functional effects on cell surface molecules such as receptors using antibody repertoire arrays specific for target cell surface molecules. Functional antibodies directed to a target and therapeutics derived from such antibodies are also provided. High throughput and parallel screening for potentially therapeutic antibodies are provided. Antibodies directed to functional epitope clusters corresponding to a target and vaccines and therapeutics derived from such antibodies are also provided.
Owner:THERACLONE SCI
Cell surface molecules as markers and therapeutic agents against kidney cancers
InactiveUS20050282168A1Efficient dosingGrowth inhibitionMicrobiological testing/measurementBiological material analysisClear cell renal cell carcinomaDisease cause
Human cell surface molecules CD70 and CD203c are expressed at higher levels in kidney carcinomas, particularly renal cell carcinomas and clear cell renal cell carcinomas, yet are expressed at low levels in normal kidney and other diseased kidney tissue, and at low levels in other tissues. CD70 and CD203c show specificity towards kidney carcinomas, particularly renal cell carcinomas and clear cell renal cell carcinomas and thus can be used as diagnostic markers and therapeutic targets for these diseases. In addition, antibodies or small molecules against these molecules could be used in treatments towards these diseases.
Owner:WYETH
Electrochemiluminescent imaging device and applications thereof
ActiveCN103913447ASimple compositionImprove light receiving rateChemiluminescene/bioluminescenceAnalysis by electrical excitationElectron multiplicationPhoton detection
The invention discloses an electrochemiluminescent imaging device which comprises an object lens, a light transmission channel, a single-photon detection electron multiplication CCD (charge coupled device) and an electrochemiluminescent generator, wherein the electrochemiluminescent generator comprises an ITO (indium tin oxide) electrode, a silver electrode and a voltage generator; the object lens, the light transmission channel and the single-photon detection electron multiplication CCD are connected in sequence; the ITO electrode is connected with the positive electrode of the voltage generator; the silver electrode is connected with the negative electrode of the voltage generator. The invention further discloses applications of the electrochemiluminescent imaging device to visual detection on hydrogen peroxide, hydrogen peroxide leaking from the surface of single cells and cell surface molecules. The electrochemiluminescent imaging device is simple in composition, high in detection flux, easy to operate and high in luminous efficiency, and can perform the parallel quick detection.
Owner:NANJING MEDICAL UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com